# Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

> **NCT01356290** · PHASE2 · RECRUITING · sponsor: **Medical University of Vienna** · enrollment: 232 (estimated)

## Conditions studied

- Medulloblastoma Recurrent
- Ependymoma Recurrent
- ATRT Recurrent
- Rare CNS Tumor Recurrent

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Thalidomide
- **DRUG:** Celecoxib
- **DRUG:** Fenofibric acid
- **DRUG:** Etoposide
- **DRUG:** Cyclophosphamide
- **DRUG:** Etoposide phosphate
- **DRUG:** Cytarabine
- **DRUG:** Temozolomide (TMZ)
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01356290
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2014-04
- **Primary completion:** 2030-04
- **Final completion:** 2030-04
- **Target enrollment:** 232 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01356290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01356290, "Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01356290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*